Ibrutinib improves the efficacy of anti‐CD19‐CAR T‐cell therapy in patients with refractory non‐Hodgkin lymphoma

The efficacy and side effects of the second‐time humanized CD19 chimeric antigen receptor (CD19‐CAR) T‐cell therapy after unsuccessful first‐time anti‐CD19‐CAR T‐cell therapy and subsequent ibrutinib salvage treatment were observed in patients with refractory B‐cell lymphoma. In our study, 3 patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Meijing, Deng, Haobin, Mu, Juan, Li, Qing, Pu, Yedi, Jiang, Yili, Deng, Qi, Qian, Zhengzi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253282/
https://www.ncbi.nlm.nih.gov/pubmed/33932067
http://dx.doi.org/10.1111/cas.14915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253282/
https://www.ncbi.nlm.nih.gov/pubmed/33932067
http://dx.doi.org/10.1111/cas.14915

Ejemplares similares